glp-1 drugs pharmaceutical companies news 2025 Beyond GLP-1: the next wave of weight-loss medication innovation Patients Face New Barriers for

M., Gibb, R

doi: 10.1007/s13300-020-00951-6 49 PackerMButlerJFilippatosGSJamalWSalsaliASchneeJet al

Although nNOS and eNOS are mainly expressed steadily in neurons and endothelial cells regardless of the cell's metabolic state, iNOS exists in trace amounts under healthy conditions and is synthesized de novo in some immunological cells, such as microglia, via inflammatory triggering (32)

10.1007/s10787-019-00643-z 17 HamaidiI.KimS

Despite selecting reference materials known for specific in vitro lung effects (Supplementary Table S1), some well-document biological responses to these materials were mild or absent in both in vitro human lung systems